The purpose of the STORM CHASER Study is to research a combination of two investigational monoclonal antibodies for the prevention of COVID-19. COVID-19 is the disease caused by the coronavirus (SARS-CoV-2). The study is looking at how well the investigational monoclonal antibodies work and how safe they are.

Antibodies are protein molecules that your body produces to help fight infections. Monoclonal antibodies are artificially produced in a laboratory and designed as possible medical treatments.

The investigational monoclonal antibodies are still in the testing and evaluation phase and are not licensed for use in the general public.

Approximately 1125 volunteers will take part in this study at all sites.

Read the full participant brochure.

Contact: uclh.stormchaser@nhs.net

Visit the study website.


You may be eligible to take part if you:

  • Have recently been in contact with someone who is confirmed to be infected with SARS-CoV-2, in the last 8 days
  • Have not had a previously confirmed diagnosis of COVID-19
  • Are over 18
  • Are not currently pregnant or planning to become pregnant

Diversity is important in clinical studies, especially for COVID-19

Research has shown that certain diseases and medications may impact people differently based on their age, gender, and genetic background, including race and ethnicity. For example, COVID-19 has disproportionally impacted both older people and minority populations.

Therefore, clinical research studies often require large numbers of volunteers from diverse populations to participate in a single study. Sometimes thousands of volunteers are needed to obtain reliable information. This helps to ensure that study medications, vaccines, or antibodies are generally safe and work for many different people, especially those most impacted by the disease or illness.

This is why we need people from different races and ethnicities to join the STORM CHASER study.